<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04451486</url>
  </required_header>
  <id_info>
    <org_study_id>N201709009</org_study_id>
    <nct_id>NCT04451486</nct_id>
  </id_info>
  <brief_title>A Phase I Study of SB Cell for the Enhanced Osseointegration of Guided Bone Regeneration in Implant Surgery</brief_title>
  <official_title>A Phase I Study to Evaluate The Use of Autologous-Derived Adult Peripheral Small Blood Stem Cells to Enhance Osseointegration of Guided Bone Regeneration in Implant Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 study to evaluate the safety profile of autologous-derived SB cells to&#xD;
      enhance osseointegration of GBR in patients undergoing dental implant surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1 study to evaluate the safety profile of autologous-derived SB cells to&#xD;
      enhance osseointegration of GBR in patients undergoing dental implant surgery.&#xD;
&#xD;
      Enrolled subjects eligible to receive GBR procedure will be sequentially assigned to 1 of 3&#xD;
      treatment cohorts as follows:&#xD;
&#xD;
      Treatment dose 1 group：1×10*5 CD61-Lin- cells /0.25mL DPBS Treatment dose 2 group：1×10*6&#xD;
      CD61-Lin- cells /0.25mL DPBS Treatment dose 3 group：1×10*7 CD61-Lin- cells /0.25mL DPBS&#xD;
&#xD;
      After receiving the autologous SB cells solution mixed with 1 mL bone substitute, each first&#xD;
      treated subject at each cohort will be followed up to 4-weeks. After the first subject at&#xD;
      each cohort (3 subjects) complete a 4-weeks follow-up period, if investigator and sponsor&#xD;
      judge that there is not either a safety concern or a dose-limiting toxicity (DLT) criteria is&#xD;
      not met, 2 additional subjects within each cohort will be enrolled. A Data Safety Monitoring&#xD;
      Committee will be conveyed after the first 3 treated subjects at each cohort complete undergo&#xD;
      the dental implant procedure (12-weeks follow-up after GBR) to evaluate the safety and&#xD;
      preliminary efficacy of SB cells administered during a GBR procedure, and will provide&#xD;
      recommendations regarding study modification, continuation to enroll next subject(s), cohorts&#xD;
      or study termination.&#xD;
&#xD;
      If the committee recommends further subject enrollment, sequential recruitment will continue&#xD;
      until subjects for each treatment cohort are enrolled, treated and followed up to 24-weeks&#xD;
      after GBR (12-weeks after dental implant) unless there is a safety concern judged by&#xD;
      investigator, sponsor, or a dose-limiting toxicity (DLT) criteria is met. Once this situation&#xD;
      occurs, the committee will assess the progress and safety data of all subjects enrolled, and&#xD;
      will provide recommendations regarding study modification, continuation to enroll next&#xD;
      subject in that or other cohorts, or will recommend study termination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2018</start_date>
  <completion_date type="Anticipated">April 25, 2021</completion_date>
  <primary_completion_date type="Actual">December 12, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Throughout the study, an average of 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The maximum tolerated dose (MTD) of autologous-derived Small Blood Stem Cells in patients undergoing dental implant surgery.</measure>
    <time_frame>Throughout the study, an average of 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Guided Bone Regeneration</condition>
  <arm_group>
    <arm_group_label>Treatment dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1x10*5 CD61-Lin- cells /0.25mL DPBS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1x10*6 CD61-Lin- cells /0.25mL DPBS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1x10*7 CD61-Lin- cells /0.25mL DPBS</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB cells</intervention_name>
    <description>1x10*5 CD61-Lin- cells /0.25mL DPBS</description>
    <arm_group_label>Treatment dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB cells</intervention_name>
    <description>1x10*6 CD61-Lin- cells /0.25mL DPBS</description>
    <arm_group_label>Treatment dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB cells</intervention_name>
    <description>1x10*7 CD61-Lin- cells /0.25mL DPBS</description>
    <arm_group_label>Treatment dose 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects 20 years old and over;&#xD;
&#xD;
          2. Sign of informed consent form;&#xD;
&#xD;
          3. Patients with one missing tooth with D2, D3 bone density;&#xD;
&#xD;
          4. Gums environment defined as alveolar bone height of 10 mm and above, bone width 8 mm&#xD;
             and above;&#xD;
&#xD;
          5. Have only one missing maxillary or mandibular posterior tooth (No. 4, 5, 6 or 7) who&#xD;
             require a GBR prior to a dental implant.&#xD;
&#xD;
          6. Bone defect(s) must be present with at least two walls missing.&#xD;
&#xD;
          7. The opposing dentition must be nature teeth or fixed crowns or bridges on natural&#xD;
             teeth or implants. Removable prostheses or dentures opposing the study implants are&#xD;
             not allowed;&#xD;
&#xD;
          8. Subject is able to understand and comply with protocol requirements, instructions and&#xD;
             protocol stated restrictions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have inadequate organ function described as below:&#xD;
&#xD;
               1. ANC &lt; 1.5 x 109/L&#xD;
&#xD;
               2. Platelets &lt; 100 x 109/L&#xD;
&#xD;
               3. Hb &lt; 9 g/dL&#xD;
&#xD;
               4. Serum bilirubin &lt; 1.5 x the upper limit of normal (ULN)&#xD;
&#xD;
               5. Aspartate aminotransferase (AST [SGOT]) &lt; 2.5 × the ULN&#xD;
&#xD;
               6. Alanine aminotransferase (ALT [SGPT]) &gt; 2.5 × the ULN&#xD;
&#xD;
               7. Serum creatinine &gt; 1.5 mg/dL or a measured creatinine clearance &lt; 60 mL/min;&#xD;
&#xD;
          2. History of neoplastic disease and had been treated with chemotherapy;&#xD;
&#xD;
          3. Uncontrolled Diabetes Mellitus;&#xD;
&#xD;
          4. Dialysis patients;&#xD;
&#xD;
          5. Patients with cardiovascular disease;&#xD;
&#xD;
          6. Osteoporosis patients and patients taking bisphosphonates;&#xD;
&#xD;
          7. History of radiation therapy to the head and neck;&#xD;
&#xD;
          8. Patients with temporomandibular disorder;&#xD;
&#xD;
          9. Pregnant or nursing women;&#xD;
&#xD;
         10. Presence of conditions requiring chronic routine prophylactic use of antibiotics&#xD;
             (history of rheumatic heart disease, bacterial endocarditis, cardiac valvular&#xD;
             anomalies, prosthetic joint replacements);&#xD;
&#xD;
         11. Medical conditions requiring prolonged use of steroids;&#xD;
&#xD;
         12. Physical handicaps that would interfere with the ability to perform adequate oral&#xD;
             hygiene;&#xD;
&#xD;
         13. Use of any investigational drug or device within the 30-day period immediately prior&#xD;
             to implant surgery on study day 0;&#xD;
&#xD;
         14. Alcoholism or drug abuse;&#xD;
&#xD;
         15. Patients infected with HIV;&#xD;
&#xD;
         16. Current smokers, ;&#xD;
&#xD;
         17. Local inflammation, including untreated periodontitis;&#xD;
&#xD;
         18. Mucosal diseases such as erosive lichen planus;&#xD;
&#xD;
         19. History of local radiation therapy;&#xD;
&#xD;
         20. Presence of osseous lesions;&#xD;
&#xD;
         21. Unhealed extraction sites;&#xD;
&#xD;
         22. Persistent intraoral infection;&#xD;
&#xD;
         23. Patients with inadequate oral hygiene or unmotivated for adequate home care;&#xD;
&#xD;
         24. Conditions or circumstances, in the opinion of the investigator, which would prevent&#xD;
             completion of study participation or interfere with analysis of study results, such as&#xD;
             history of non-compliance, or unreliability.&#xD;
&#xD;
         25. Patient with a pathology present near the site of dental implantation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Da-Yen Wang, PhD</last_name>
    <phone>+886-2-2736-1661</phone>
    <phone_ext>5401</phone_ext>
    <email>dpw1@tmu.edu.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sheng-Wei Feng, PhD</last_name>
    <phone>+886-2-2736-1661</phone>
    <phone_ext>5401</phone_ext>
    <email>shengwei@tmu.edu.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Taipei Medical University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>110</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Da-Yen Wang, PhD</last_name>
      <phone>+886-2-2736-1661</phone>
      <phone_ext>5401</phone_ext>
      <email>dpw1@tmu.edu.tw</email>
    </contact>
    <contact_backup>
      <last_name>Sheng-Wei Feng, PhD</last_name>
      <phone>+886-2-2736-1661</phone>
      <phone_ext>5401</phone_ext>
      <email>shengwei@tmu.edu.tw</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&amp;r=8&amp;f=G&amp;l=50&amp;co1=AND&amp;d=PTXT&amp;s1=%22SOMATIC+STEM+CELLS%22&amp;s2=Stembios&amp;OS=%22SOMATIC+STEM+CELLS%22+AND+Stembios&amp;RS=%22SOMATIC+STEM+CELLS%22+AND+Stembios</url>
    <description>Patent Application Publication</description>
  </link>
  <reference>
    <citation>Schneider R. Prosthetic concerns about atrophic alveolar ridges. Postgrad Dent. 1999;6(2):3-7.</citation>
    <PMID>11360322</PMID>
  </reference>
  <reference>
    <citation>de Baat C, Kalk W, van 't Hof M. Factors connected with alveolar bone resorption among institutionalized elderly people. Community Dent Oral Epidemiol. 1993 Oct;21(5):317-20.</citation>
    <PMID>8222609</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 15, 2020</study_first_submitted>
  <study_first_submitted_qc>June 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2020</study_first_posted>
  <last_update_submitted>June 28, 2020</last_update_submitted>
  <last_update_submitted_qc>June 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SB cell、autologous、Osseointegration</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

